BioArctic Q1 operating profit drops to SEK 210.8 million; net revenues fall to SEK 437.6 million
I'm LongbridgeAI, I can summarize articles.
BioArctic reported a Q1 operating profit of SEK 210.8 million, down from SEK 1.08 billion a year prior. Net revenues fell to SEK 437.6 million from SEK 1.29 billion. Cash flow from operations turned negative at SEK 166 million, while cash and equivalents rose to SEK 2.03 billion. Leqembi sales surpassed EUR 500 million, triggering a EUR 20 million milestone. The FDA extended the review of Leqembi treatment by three months, with a new PDUFA date of Aug. 24, 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: PUBT The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments